Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 924 matching trials from the live ClinicalTrials.gov search.
Conditions
Psoriasis
Interventions
vehicle foam, calcipotriene, calcipotriene + clobetasol propionate
Drug
Lead sponsor
Leon Kircik, M.D.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Taclonex Ointment and Hydrogel Patch, Taclonex Ointment
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Aventura, Florida • Palm Harbor, Florida • Sarasota, Florida + 9 more
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Irvine, California • Fargo, North Dakota
Conditions
Psoriasis, Pregnancy, Psoriatic Arthritis, Crohn Disease
Interventions
Ustekinumab, Guselkumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
1
States / cities
La Jolla, California
Conditions
Psoriasis
Interventions
Topical Rose Bengal, 0.005%
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Miami, Florida • Chapel Hill, North Carolina • Austin, Texas
Conditions
Scalp Psoriasis
Interventions
clobetasol propionate spray 0.05%, Vehicle spray
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Los Angeles, California • Evansville, Indiana • New York, New York + 1 more
Active, not recruiting Phase 2 Interventional

A Study of SPY072 in Rheumatic Disease

NCT07148414
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease
Interventions
SPY002-072, Placebo
Drug
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Avondale, Arizona • Tucson, Arizona • Chula Vista, California + 14 more
Conditions
Psoriasis
Interventions
Acitretin 25Mg Oral Capsule, Excimer laser, Tazarotene 0.1% Gel,Top, Sham excimer laser
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Chronic Plaque Psoriasis
Interventions
Topical roflumilast
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
68
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 58 more
Conditions
Plaque Psoriasis
Interventions
188-0551 Spray, RLD
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Thousand Oaks, California • Miami, Florida
Conditions
Psoriasis
Interventions
CTA018 cream
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Chicago, Illinois + 12 more
Conditions
Psoriatic Arthritis
Interventions
TILD sub-cutaneous (SC) injection
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
41
States / cities
Dothan, Alabama • Gilbert, Arizona • Mesa, Arizona + 36 more
Conditions
Psoriasis
Interventions
Tapinarof
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
East Windsor, New Jersey
Conditions
Plaque-type Psoriasis
Interventions
secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more
Completed No phase listed Observational Results available

Psoriatic Arthritis Research Collaborative: Biologic Sub-Study

NCT03378336
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 89 Years
Enrollment
171 participants
Timeline
2017 – 2023
U.S. locations
4
States / cities
New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Completed Not applicable Interventional

Biologics Anchoring Study

NCT03026153
Conditions
Moderate-to-severe Psoriasis
Interventions
Control Group Oral Survey 1, Intervention Group Oral Survey 2
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Scleroderma
Interventions
Mindfulness Based Stress Reduction (MBSR), Control
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
bimekizumab, ustekinumab, placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
6 Years to 17 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
7
States / cities
Fountain Valley, California • Los Angeles, California • Northridge, California + 4 more
Conditions
Dermatitis, Psoriasis
Interventions
Narrowband Ultraviolet B (TL-01UVB) Therapy, Topical Psoralen plus ultraviolet A (PUVA)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Psoriasis Vulgaris
Interventions
deucravacitinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Psoriasis
Interventions
risankizumab, secukinumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Glendale, Arizona • Phoenix, Arizona • Bakersfield, California + 24 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

NCT03418493
Conditions
Psoriasis
Interventions
LY3316531 - IV, LY3316531 - SC, Placebo - IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland